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Multidrug resistance (MDR) is a signiﬁcant clinical problem in the chemotherapy of osteosarcoma
and has been linked to the cellular expression of several multidrug-efﬂux transporters such as
MDR1/P-gp. Our inhibition of the transcription factor Trps1 led to repression of MDR1/P-gp while
its overexpression resulted in upregulation of MDR1/P-gp. Flow cytometric analysis suggested Trps1
increased the release of several anti-cancer drugs, thus decreasing their accumulation. Immunohis-
tochemical analysis of clinical samples indicated that the expression of Trps1 directly correlated
with MDR1/P-gp. Trps1 inhibited TGFbeta-1 and directly bound to the MDR1 promoter. Our data
demonstrate a role for Trps1 in the regulation of MDR1 expression in osteosarcoma.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteosarcoma is the most prevalent primary malignant bone
tumor. The prognosis was very poor prior to the discovery of che-
motherapy [1,2]. However, the development of multidrug resis-
tance (MDR), in which tumor cells become resistant to a wide
spectrum of anti-cancer agents with different structures or differ-
ent target sites [3], severely limits the success of chemotherapy
in osteosarcoma. The human MDR gene 1 (MDR1), which encodes
the membrane-located efﬂux pump P-glycoprotein (P-gp), plays an
important role in the drug resistance process [4,5]. Overexpression
of MDR1/P-gp resulted in an active efﬂux of anti-cancer agents
from cells, thus lowering intracellular drug concentrations and
inducing cancer cell resistance to chemotherapeutic drugs, such
as doxorubicin and paclitaxel [3,6,7].
Tricho-rhino-phalangeal syndrome 1 (TRPS1) is a gene involved
in Tricho-rhino-phalangeal syndrome (TRPS), which is character-
ized by craniofacial and skeletal malformations [8]. It encodes atranscription factor that contains nine zinc-ﬁnger domains, includ-
ing a GATA-type zinc ﬁnger through which it binds DNA [8]. Trps1
is found in malignant tumor cells and has been suggested as a
promising cytologic tumor marker in breast cancer and prostatic
carcinoma [9–11]. Furthermore, Trps1 enhanced chondrogenesis
and apoptosis in ATDC5 cells [12].
Whether Trps1 regulates the MDR in osteosarcoma through
MDR1 gene expression is quite a signiﬁcant question for improving
the poor prognosis of drug-resistance osteosarcoma. We have
occasionally observed a positive correlation between MDR1/P-gp
and TRPS1 in our clinical samples of osteosarcoma. The putative
promoter region of MDR1 has three GATA box-like sequences to
which Trps1 may bind. We therefore hypothesized that the silenc-
ing of TRPS1 by plasmid-mediated expression of small interfering
RNA (siRNA) results in the downregulation of MDR1/P-gp. If so,
MDR in clinical chemotherapy could be partly reversed through
downregulating Trps1. In this study, to elucidate the regulating ef-
fect of Trps1 on MDR in osteosarcoma, we examined the functional
interactions between Trps1 and MDR1/P-gp in three typical osteo-
sarcoma cell lines by both downregulation and upregulation of
Trps1. Furthermore, we performed immunohistochemistry on the
tissues of osteosarcoma patients to analyze the expression of both
proteins and to evaluate the predictive signiﬁcance of Trps1 for
MDR1/P-gp.
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2.1. Clinical samples
74 parafﬁn-embedded samples without decalciﬁcation were
diagnosed as osteosarcoma at the Department of Pathology of
Qilu Hospital of Shandong University from 2005 to 2011. Nine
osteoid osteoma samples were also collected during the same
period. We obtained prior patient consent and approval from
the Institutional Research Ethics Committee of Shandong Medical
University.2.2. Cell lines and culture
Human osteosarcoma cell lines U2-OS and Saos-2 were pur-
chased from the American Type Culture Collection (Manassas,
VA, USA). The MNNG/HOS Cl #5 was purchased from Type Culture
Collection of the Chinese Academy of Sciences (Shanghai, China).
U2-OS and MNNG cells were cultured in Dulbecco’s modiﬁed Ea-
gle’s medium (Hyclone, Logan, UT, USA) (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS). Saos-2 cells
were maintained in McCoy’s 5A culture medium (Gibco BRL, Grand
Island, NY, USA) containing 10% FBS. All cells were kept at 37 C in
a humidiﬁed atmosphere of 5% CO2 and were free from myco-
plasma infection.2.3. Plasmids
siRNA oligonucleotide sequences targeted at TRPS1 were: for-
ward 50-GATCCCC GGCCTTTAAACATCATTAA TTCAAGAGA TTAAT-
GATGTTTAAAGGCCTTTTTGGAAA-30 and reverse 50-AGCTTT
TCCAAAAATTAATGATGTTTAAAGGCCTCTCTTGAAGGCCTTTAAACAT
CATTAAGGG-30. Small hairpin siRNA sequences were synthesized,
annealed, and then cloned into the pSUPER. neo + GFP expression
vector usingT4DNA ligase to generate thepSUPER-siTRPS1plasmid.
The control vector pSUPER-siNC was generated as described previ-
ously [13]. The human TRPS1 Cloning Vector was purchased from
Open Biosystems (Thermo Scientiﬁc, Massachusetts, USA), and then
the target genewas subcloned into amammalian expression vector,
pcDNA3.1 (+) (Invitrogen, Carlsbad, CA,USA). Anegative control vec-
tor was constructed as with the previous control plasmid.2.4. Transfection of osteosarcoma cells
1  106 cells were seeded in 4 ml of DMEM with 10% FBS in
each well of 6-well plates 24 h prior to transfection. For each
well, either 4 lg of pSUPER-siTRPS1 or pcDNA3.1-TRPS1 plasmid
DNA were diluted in 400 lL of serum-free DMEM. Then, 4 lL of
TurboFect in vitro Transfection Reagent (Fermentas, Burlington,
Canada) was added to the diluted DNA and mixed by pipetting
before incubating for 20 min at room temperature. 400 lL of
the TurboFect/DNA mixture was added drop-wise to each well
without removal of the previous culture medium. The plates were
gently rocked to distribute the complexes evenly and were then
incubated for 6 h. Non-target siRNA plasmids (pSUPER-siNC and
pcDNA3.1-siNC) were used as controls. Three groups of osteosar-
coma cells were transduced: U2-OS pSUPER-siTRPS1, U2-OS pSU-
PER-siNC, U2-OS pcDNA3.1-TRPS1, U2-OS pcDNA3.1-NC, Saos-2
pSUPER-siTRPS1, Saos-2 pSUPER-siNC, Saos-2 pcDNA3.1-TRPS1,
Saos-2 pcDNA3.1-NC, MNNG pSUPER-siTRPS1, MNNG pSUPER-
siNC, MNNG pcDNA3.1-TRPS1, and MNNG pcDNA3.1-NC. Cells
were then grown for 3 days.2.5. Quantitative real-time PCR (qRT-PCR)
An RNA Iso-Plus kit (Takara, Otsu, Japan) was used to extract to-
tal cellular RNA, and the ﬁrst strand DNA was synthesized with
Omniscript Reverse Transcriptase (TOYOBO, Osaka, Japan) accord-
ing to the manufacturers’ instructions. All reactions were per-
formed using eUltraSYBR Mixture (with ROX) (Beijing CoWin
Bioscience Co., Ltd., Beijing, China), 250 nM primers (Invitrogen),
and 100 ng cDNA in a 20 ll total reaction volume following the
manufacturer’s instructions. All samples were run in quadruplicate
in three independent experiments, and the results were normal-
ized against the endogenous internal control beta-actin. The
qRT-PCR primers are listed in the Supplement.
2.6. Western blot analysis
Cellular protein extracts were prepared as described previously
[13]. Samples of 600 lg cellular proteins per lane were resolved by
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and electro-
phoretically blotted onto a poly-vinylidene diﬂuoride ﬁlter (Milli-
pore, Billerica, MA, USA). Subsequently, ﬁlters were blocked with
5% fat-free milk powder in TBS at room temperature for 2 h prior
to incubation with relevant primary antibodies overnight at 4 C,
washing, and probing again with species-speciﬁc secondary anti-
bodies coupled with horseradish peroxidase. Immunoreactivity
was detected using an enhanced chemiluminescence (ECL) ad-
vanced western blotting detection kit (Millipore). The primary
antibodies were as follows: goat polyclonal antibody Trps1 (sc-
26974; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, diluted
1:400) [14,15], TGF-b1 rabbit antibody (18978-1-AP; Proteintech,
Wuhan, China, diluted 1:500) [16], anti-P-gp mouse monoclonal
antibody (mAb) (C494; Merck KgaA, Darmstadt,Germany, diluted
1:500), and mouse mAb beta-actin (TA-09; Zhongshan Golden-
bridge Biotechnology, Beijing, China, diluted 1:2000) as a total pro-
tein internal control.
2.7. Efﬂux assay
Rh123 efﬂux assays were performed as previously described
[3], with minor modiﬁcations. Approximately transfected 1  106
cells were incubated with 5 lM Rh123 at 37 C for 30 min. After
washing with cold PBS, cells were cultured in Rh123-free culture
medium at 37 C for 1 h and then harvested to measure Rh123 ef-
ﬂux. The retained cellular ﬂuorescence intensity was measured by
ﬂow cytometry (BD Accuric6, NY, USA). Each cell subline was
tested three times. Data were analyzed with FlowJo 7.6.5 (Stanford
University, California, USA).
2.8. Cytotoxicity assay for cell survival
The 3-(4.5-dimethylthiazed-2-yl)-2,5-diphenylterazolium bro-
mide (MTT, Sigma, San Francisco, CA, USA) assay was used to assess
the effect of Trps1 on the chemosensitivity of osteosarcoma cells to
anti-cancer drugs. Transfected cellswere plated in a 96-well plate at
a density of 8  103 cells per well for 24 h and then incubated with
different concentrations of paclitaxel for another 24 h and cisplatin,
doxorubicin, 5-Fu (DalianMeilunbioCo., Ltd., Dalian, China) for 48 h.
TheMTTassaywasperformed following themanufacturer’s instruc-
tions. Optical densities (ODs) were measured using a spectrometric
absorbance of 570 nm against a background of 630 nm on a Bio-Rad
microplate reader (Hercules, CA, USA). Cell viability was measured
as: (A570 anti-cancer drug+/A570 anticancer drug)  100%. We
plotted dose–response curves and calculated IC50 values from three
independent experiments [17].
M. Jia et al. / FEBS Letters 588 (2014) 801–810 8032.9. Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed in U2-OS cells using the ChIP assay
kit (Beyotime, Beijing, China). Brieﬂy, 1  106 cells were treated
with 1% formaldehyde for 15 min for crosslinking, and chromatin
samples were immunoprecipitated using an anti-Trps1 antibody
(sc-26974) [14,15], anti-P-gp mouse mAb (C494), or control rabbit
IgG antibody (Beyotime) after ultrasonication. Bindings of Trps1 to
the MDR1 promoter were analysed by PCR. The control primers, 50-
CTCCATCCTGGCCTCGCTGT-30 and 50-GCTGTCACCTTCACCGTTCC-30,
were used to amplify non-speciﬁc DNA (beta-actin). The binding
sites were predicted by JASPAR CORE database and TFSEARCH.
The speciﬁc primers were designed by Primer-BLAST of NCBI.
PCR conditions were as follows: 94 C for 1 min, 60 C for 30 s,
and 72 C for 30 s for 40 cycles and a ﬁnal extension for 10 min
at 72 C. PCR products were separated on 2% agarose gel and visu-
alized with GelRed (Biotium, Shanghai, China). The PCR primers are
listed in the Supplement.
2.10. Histologic and immunohistochemical analyses
The parafﬁn-embedded osteosarcoma tissues were sliced into
4 lm thick sections. Immunostaining was performed using a
microwave-based antigen retrieval technique [18]. The antibodies
used in this study included Trps1 (sc-26974, diluted 1:200)
[14,15] and anti-P-gp mouse mAb (C494, diluted 1:1000) for
immunohistochemistry. Trps1 staining was evaluated in the nu-
cleus. Brieﬂy, staining was scored semi-quantitatively for intensity
(0 = no expression; 1 = weak; 2 = moderate; 3 = strong) and per-
centage of positive cells (1 = 0–24%; 2 = 25–49%; 3 = 50–74%, and
4 = 75–100%) [10,19]. Cut-off levels of the sum of scores were ap-
plied as 0 for negative, 1–3 for weak positive, and 4–7 for strong
positive. The scoring of P-gp immunostaining was evaluated in
the membrane in accordance with previous studies [20]. A P-gp
score P2 was considered positive [21,22].
2.11. Statistical analysis
Statistical analysis was performed using SPSS 18.0 (SPSS, Chi-
cago, IL, USA) and GraphPad Prism 5 (GraphPad Software, Inc.,
San Diego, CA, USA). All experiments were performed in triplicate,
and all data were presented as mean ± S.E.M. The Student’s t-test
was used to determine statistical signiﬁcance. Comparisons be-
tween two groups were performed using the paired t-test, and
the Pearson Chi-Square tests or Fisher’s Exact Test was used to
evaluate the correlation between Trps1 expression and the
MDR1/P-gp, if appropriate. P < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Reduced TRPS1 and MDR1 mRNA and protein expression
in response to Trps1 inhibition
We performed transient knockdown experiments with TRPS1
siRNA plasmids. qRT-PCR veriﬁed the effects of TRPS1 siRNA-med-
iated inhibition of MDR1 mRNA expression. TRPS1 mRNA levels
were suppressed by 76.7 ± 7.3%, 85.2 ± 4.1%, and 83.4 ± 5.4% in
TRPS1-silenced U2-OS, MNNG, and Saos-2 cells, respectively. As
shown in Fig. 1A–C, the relative expressions of MDR1 mRNA in
U2-OS pSUPER-siTRPS1, MNNG pSUPER-siTRPS1, and Saos-2 pSU-
PER-siTRPS1 cells were an average of 3.4–6.5-fold lower than the
control cells.Western blot analysis revealed that the U2-OS and MNNG cell
sublines expressed Trps1 and MDR1/P-gp, but we could not detect
any MDR/P-gp expression in TRPS1-silenced or TRPS1-overexpres-
sed Saos-2 cell lines (Fig. 1H). When osteosarcoma cells were trea-
ted with the siTRPS1 vector, the MDR1/P-gp was consequently
decreased in the total protein (Fig. 1D–G), especially in MNNG
pSUPER-siTRPS1 cells which showed 95.4 ± 4.3% less than MNNG
cells. Protein expression was consistent with the mRNA levels.
3.2. Effects of increased Trps1 expression on MDR1/P-gp mRNA and
protein levels
We overexpressed Trps1 in osteosarcoma cell lines to monitor
the effects on endogenous MDR1/P-gp mRNA expression. An aver-
age of 4.2–8.4-fold higher MDR1/P-gp mRNA expression was ob-
served by RT-PCR when Trps1 was overexpressed (Fig. 1A–C).
The changes were signiﬁcant in all cell groups (P < 0.05).
Increased Trps1 expression promoted MDR1/P-gp protein
expression in the osteosarcoma cells in which it was detectable
(U2-OS and MNNG). This was further evidence of Trps1’s effects
on MDR in osteosarcoma. In TRPS1-overexpressing U2-OS and
MNNG cells, MDR1/P-gp protein levels were 2.1 ± 0.4 and
2.2 ± 0.3-fold more, respectively, than control cells (Fig. 1D–I).
Results for proteins showed the same trend as the mRNA levels.
3.3. Trps1 regulates multidrug sensitivity of osteosarcoma cells
Cytotoxicity assays showed a decrease in MDR1/P-gp function
in TRPS1-silenced cells. On the contrary, TRPS1-expressing cells
had less sensitivity to anti-cancer drugs as evaluated by MTT assay
(Fig. 2 shows MTT for doxorubicin only). The dose–response curves
for drug concentrations and cell viability indicated an increase in
sensitivity to doxorubicin, paclitaxel, cisplatin, and 5-Fu in
TRPS1-silenced cells (Fig. 2 and Supplement). As shown in Table 1,
IC50 values of the four anti-cancer drugs all decreased remarkably
after TRPS1 interference. In Fig. 3, the IC50 values of U2-OS pSUPER-
siTRPS1 cells were suppressed by 52.8 ± 4.5%, 49.8 ± 5.2%,
44.2 ± 2.9%, and 54.7 ± 2.7% in treatment of doxorubicin, paclitaxel,
cisplatin, and 5-Fu, respectively. In addition, when we transfected
full-length TRPS1 plasmid into the three cell lines, sensitivity to
doxorubicin, paclitaxel, cisplatin, and 5-Fu was signiﬁcantly de-
creased (Fig. 3 and Supplement), indicating that Trps1 is responsi-
ble for MDR of osteosarcoma (Table 1).
3.4. Alteration of MDR1/P-gp function as an efﬂux pump
in Trps1-inﬂected cells
The functional efﬂux assay was based on the extrusion of
Rh123, a ﬂuorescent P-gp substrate. Rh123 ﬂuorescence intensity
was examined to compare MDR1/P-gp function among the three
cell lines. To observe whether cells with altered expression of
Trps1 show inﬂuence of the MDR1/P-gp-mediated efﬂux function,
siTRPS1 vectors and full-length TRPS1 plasmids were transfected
to separate osteosarcoma cells. The retained ﬂuorescence intensity
in each negative control group was set as the background. After 1 h
of incubation in Rh123-free culture medium, a rapid reduction in
intracellular Rh123 was observed in all TRPS1-transfected cells.
We also noticed a rightward shift in the ﬂuorescence peak associ-
ated with cellular inhibition of TRPS1 (Fig. 4). Similar results were
found in repeated experiments. This also conﬁrmed that Trps1
in fact inﬂuences the drug resistance of osteosarcoma through
affecting MDR1/P-gp efﬂux function. Therefore, Trps1 increased
MDR1/P-gp-mediated Rh123 efﬂux.
Fig. 1. Changes in Trps1 and MDR1/P-gp mRNA and protein expression in response to TRPS1 knockdown and transient transfection. qRT-PCR for the expression of TRPS1 and
MDR1 mRNA in (A) U2-OS, (B) MNNG, and (C) Saos-2 cell sublines. (⁄P < 0.05, ⁄⁄P < 0.01, respectively). (D and F) Western blots showing a decrease in MDR1/P-gp and Trps1
expression in TRPS1-silenced osteosarcoma cells and an increase in TRPS1-overexpressing cells. (H) Western blots showing changes in Trps1 expression according to down-
and upregulation of Trps1. MDR1/P-gp protein could not be detected in Saos-2 cells (E, G and I). Changes in Trps1 and MDR1/P-gp proteins were all signiﬁcant (⁄P < 0.05,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, respectively).
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in osteosarcoma
Trps1 and MDR1/P-gp expression was heterogeneous within
the tumors (Fig. 5). We observed no immunohistochemical stain-
ing of the two markers in 9 osteoid osteoma samples. The stainings
of TRPS1 and MDR1/P-gp by IHC in human patients were shown in
Table 2. Statistical analyses indicated that the immunohistochem-
ical expression of Trps1 directly correlated with MDR1/P-gp in all
osteosarcoma cases (P < 0.01). Signiﬁcant correlations were found
between Trps1 and MDR1/P-gp expression in all osteosarcoma
patients (r = 0.478, P < 0.01, Fisher’s Exact Test).
3.6. Trps1 inhibits TGFbeta-1 expression in osteosarcoma cells
There was a reduction of TGFbeta-1 mRNA and protein levels
compared with negative controls. The amount of TGFbeta-1 mRNA
was signiﬁcantly reduced to 19.2% (mean) 48 h after TRPS1 trans-
fection and increased to 302.1% (mean) during TRPS1 inhibition
(Fig. 6A). The TGFbeta-1 protein level decreased to 10.1% (mean)
after increased TRPS1 expression. The protein level of TGFbeta-1reached up to 200.1% (mean) following pSUPER-siTRPS1
transfection.
3.7. Trps1 binds the MDR1 promoter through an intrinsic site
We examined the MDR1 gene sequence and identiﬁed a puta-
tive Trps1 binding site (ACTATCTTGT) in 932 to 925 bp of the
MDR1 gene promoter (Fig. 6C). A ChIP assay with U2-OS cell ex-
tracts and unique primers derived from the GATA3-binding site
showed speciﬁc Trps1 binding (Fig. 6D), while we could not detect
any binding in two additional GATA-like sequences. Moreover, we
could not detect any binding by using IgG and unrelated antibodies
(Fig. 6D). All experiments were performed in triplicate, and the re-
sults were reproducible.
4. Discussion
Osteosarcoma is the most common malignant bone tumor with
a peak incidence in children and young adolescents, suggesting a
role for rapid bone growth in its pathogenesis [23]. Besides sur-
gery, the major treatment of osteosarcoma is chemotherapy, and
Fig. 2. Dose–response curves for doxorubicin concentrations and cell viability. Osteosarcoma cells were treated with four concentrations of doxorubicin for 48 h. Cell viability
was calculated relative to untreated controls. (A, C, and D) TRPS1 knockdown resulted in an increase in doxorubicin cytotoxicity. (B, D, and F) TRPS1 transfection and
upregulation of MDR1/P-gp decreased doxorubicin cytotoxicity. Data points represent averages from triplicates in a representative experiment, and their standard errors are
depicted.
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niﬁcantly improved the prognosis [24]. However, despite the use
of many therapeutic methods, the ﬁve-year survival rate for oste-
osarcoma is still lower than 50% [25–27].
Rapid development of cross-resistance against current drugs
has always been the major obstacle in the chemotherapy of osteo-
sarcoma. One major mechanism of MDR is the expression of the
MDR1-encoding P-gp [28,29], which is responsible for resistance
to several unrelated cancer chemotherapeutic drugs [5]. Overex-
pression of the efﬂux pump MDR1/P-gp results in the decreased
accumulation and toxicity of many anti-cancer drugs, such as
doxorubicin, cisplatin, and etoposide, leading to chemotherapeutic
failure. Although several inhibitors/modulators of MDR1/P-gp have
been developed, cytotoxic effects and adverse pharmacokinetics
have prohibited their use [30]. Currently available inhibitors also
lack the potency to completely reverse the MDR phenotype at clin-
ically-attainable concentrations [31,32].In our routine studies, we have occasionally found a positive
correlation between MDR1/P-gp and TRPS1 in clinical samples of
osteosarcoma. The TRPS1 gene encodes a protein with nine zinc
ﬁnger motifs, including one GATA-type DNA-binding domain,
while two at the carboxyl terminus show homology with the Ikaros
family of lymphoid transcriptional factors [33]. Trps1 has been re-
ported as a transcriptional repressor interacting with the dynein
light chain and ring ﬁnger protein 4 in the nucleus [34,35]. It en-
hanced chondrogenesis and apopotosis in ATDC5 cells [12], while
increased expression of Trps1 has been generally correlated with
better prognosis and a mesenchymal-to-epithelial cell transition
in human breast cancers [10,14]. However, the molecules that lie
upstream and downstream of Trps1 are largely unknown.
In order to conﬁrm our occasional ﬁndings, we used classical
osteosarcoma cell lines to investigate the relationship between
Trps1 and MDR1/P-gp. Fortunately, we detected TRPS1 expression
in U2-OS, MNNG, and Saos-2 cells by qRT-PCR and immunoblotting
Table 1
The IC50 values of the four chemotherapeutic drugs in different groups of cells.
Cells Drugs
Doxorubicin (lM) Paclitaxel (ng/ml) Cisplatin (lg/ml) 5-Fu (mM)
U2-OS 1.526 ± 0.01220 0.2893 ± 0.01124 1.485 ± 0.04486 1.454 ± 0.007211
U2-OS pSUPER-siNC 1.535 ± 0.01372 0.2641 ± 0.002338 1.502 ± 0.04752 1.387 ± 0.02517
U2-OS pSUPER-siTRPS1 0.7110 ± 0.004366 0.1484 ± 0.002774 0.7445 ± 0.01294 0.6271 ± 0.003056
U2-OS pcDNA3.1-NC 1.534 ± 0.02195 0.2909 ± 0.005100 1.361 ± 0.02150 1.406 ± 0.03559
U2-OS pcDNA3.1-TRPS1 2.194 ± 0.03950 0.7266 ± 0.01011 2.237 ± 0.03619 2.402 ± 0.01021
MNNG 1.573 ± 0.09854 4.992 ± 0.5628 0.6335 ± 0.03186 0.3029 ± 0.03770
MNNG pSUPER-siNC 1.561 ± 0.09705 4.249 ± 0.1074 0.625 ± 0.02735 0.2818 ± 0.03158
MNNG pSUPER-siTRPS1 0.5958 ± 0.02001 1.925 ± 0.07319 0.3191 ± 0.01143 0.05873 ± 0.008135
MNNG pcDNA3.1-NC 1.457 ± 0.1239 4.856 ± 0.1930 0.6519 ± 0.02547 0.3264 ± 0.02287
MNNG pcDNA3.1-TRPS1 3.034 ± 0.09861 8.004 ± 0.3373 1.091 ± 0.02339 1.016 ± 0.06071
Saos-2 0.9429 ± 0.01649 0.1849 ± 0.02041 0.3006 ± 0.006664 1.292 ± 0.1203
Saos-2 pSUPER-siNC 0.9165 ± 0.04212 0.1787 ± 0.01243 0.2881 ± 0.01760 1.165 ± 0.1691
Saos-2 pSUPER-siTRPS1 0.5422 ± 0.02750 0.07005 ± 0.009107 0.1633 ± 0.004950 0.264 ± 0.02917
Saos-2 pcDNA3.1-NC 0.9044 ± 0.05756 0.1267 ± 0.01578 0.294 ± 0.009351 1.318 ± 0.1609
Saos-2 pcDNA3.1-TRPS1 1.543 ± 0.1267 0.5161 ± 0.04522 0.4851 ± 0.02106 3.268 ± 0.3997
The IC50 values of doxorubicin, paclitaxel, cisplatin, and 5-Fu were averaged from triplicates of MTT assays with SPSS 18.0, presented as mean ± S.E.M. IC50 values of the four
anti-cancer drugs were all decreased after TRPS1 silence. On the contrary, TRPS1-transfected cells had an increased IC50 values comparing with negative control.
Fig. 3. IC50 values of four chemotherapeutic drugs in U2-OS cells. (A–D) The IC50 for the four anti-cancer drugs was averaged from triplicates of MTT assays with GraphPad
Prism 5. Error bars indicate standard error. IC50 values of doxorubicin, paclitaxel, cisplatin, and 5-Fu all decreased signiﬁcantly in TRPS1-silenced U2-OS cells. The Trps1
overexpressing cells had IC50 values higher than the control groups. (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, respectively).
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immunoblotting assays. We inhibited and overexpressed TRPS1
simultaneously and observed identical changes inMDR1/P-gp com-
pared with controls. This may promote the positive relationshipbetween them. These cells also exhibited statistically signiﬁcant
resistance to doxorubicin, paclitaxel, cisplatin, and 5-Fu toxicity
in cell viability assays. Thus, we concluded the changes in Trps1
expression directly affect the toxicity of anti-cancer drugs in vitro.
Fig. 4. Rh123 efﬂux assay for determining the effects of Trps1 on the P-gp function of osteosarcoma cells. The P-gp efﬂux function was measured by ﬂow cytometry. Cells
were ﬁrst exposed to 5 lMRh123 for 30 min, then washed, and incubated in Rh123-free culture medium for 1 h. Estimated cellular ﬂuorescence showed that P-gp function as
an efﬂux pump decreased and was activated remarkably in TRPS1-silenced and TRPS1-tansfected osteosarcoma cells compared to controls. The results were consistent in
duplicate experiments.
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treatments, which is additional proof that the effects of Trps1 act
on MDR1/P-gp.
The exact mechanisms explaining the regulation of human P-gp
expression by Trps1 is still unknown. By studying sequence of the
promoter fragment, we found three GATA box-like sequences to
which Trps1 may bind. Then, we conﬁned a single Trps1 binding
site in the MDR1/P-gp promoter. We also analyzed TGFbeta-1,
which has been reported to inhibit MDR1 in human glioma cells
[36]. Consistent with our previous study, it was also inhibited by
Trps1 in the context of human osteosarcoma [37].
We observed Trps1-positive nuclear staining in 24/74 cases and
MDR1/P-gp membrane staining in 12/74 cases. Only non-decalci-
ﬁed sections were used in order to exclude the inﬂuence of decal-
cifying ﬂuid on immunohistochemistry. There was a direct
correlation between Trps1 and MDR1/P-gp with the Pearson corre-
lation coefﬁcient reaching to 0.478 and a P value smaller than 0.01.This suggested the likelihood that MDR1/P-gp is affected and reg-
ulated by Trps1. The absence of Trps1 and MDR1/P-gp in osteoid
osteoma is consistent since these are benign lesions and not malig-
nant as osteosarcoma.
Most current treatment protocols of osteosarcoma including a
variety of doxorubicin, cisplatin, high-dose methotrexate, and
ifosfamide have greatly improved the prognosis [38,39]. All these
drugs can be pumped out from the tumor cells by membrane-lo-
cated efﬂux pump P-gp, thus severely limiting the success of che-
motherapy. These drugs have antitumor activity in osteosarcoma,
while doxorubicin and cisplatin are frequently used as the basis
of treatment, and there is evidence that combinations with meth-
otrexate and/or ifosfamide might provide additional beneﬁt over
two-drug schedules [40]. However, the histological response to
preoperative chemotherapy was evaluated by MRI or necrosis per-
centage of the tumor during the surgery after several cycles of che-
motherapy [40,41]. Since MDR1/P-gp plays a very important role in
Fig. 5. Expression of Trps1 and MDR1/P-gp markers in human osteosarcoma. Representative ﬁelds from tumor cores showing examples of positive Trps1 and MDR1/P-gp
(upper row, 400) and negative Trps1 and MDR1/P-gp (lower row, 400). Trps1 exhibited nuclear immunoreactivity and MDR1/P-gp membrane immunoreactivity. The
positive group tissues were from a single patient, and the negative group was from another patient. Correlations among both markers from these human cases were analyzed
algorithmically. Results are depicted in Table 3.
Table 2
TRPS1 and MDR1/P-gp scores by IHC in human bone tumor tissue.
Tumor type Number TRPS1 score TRPS1% positive MDR1/P-gp score MDR1/P-gp% positive
Negative Weak positive Strong positive Negative Positive
Osteoid osteoma 9 9 0 0 0% (0/9) 9 0 0% (0/9)
Conventional osteosarcoma 62 39 13 10 37.1% (23/62) 50 12 19.4% (12/62)
Low grade central osteosarcoma 5 4 1 0 20% (1/5) 5 0 0% (0/5)
Parosteal osteosarcoma 5 5 0 0 0% (0/5) 5 0 0% (0/5)
Periosteal osteosarcoma 1 1 0 0 0% (0/1) 1 0 0% (0/1)
Telangiectatic osteosarcoma 1 1 0 0 0% (0/1) 1 0 0% (0/1)
Table 3
Correlation among TRPS1 expression and MDR1/P-gp in human osteosarcoma cancer.
MDR1/
P-gp
n TRPS1expression P value Spearman Value
(r)
P
value
<1 P1 Correlationa
All cases
Negative 62 48 14 <0.001b 0.478 <0.001
Positive 12 2 10
a The Spearman correlation was used to compare the degrees of correlation.
Positive numbers reﬂected direct correlation, and negative numbers reﬂected
inverse correlation.
b Fisher’s Exact Test for one in four cells have expected count less than 5.
808 M. Jia et al. / FEBS Letters 588 (2014) 801–810the chemotherapy of osteosarcoma [20], the MDR1/P-gp-predictive
marker Trps1 may forecast histological responses to certain MDR1/
P-gp speciﬁc substrates such as doxorubicin and cisplatin. If drug
resistance were conﬁrmed by biopsy (immunochemistry of the tu-
mor tissue from the core needle biopsy or open biopsy), early sur-
gery obtaining wide margins or a suitable chemotherapy regimen
could be chosen to make a better protocol [40]. Since the effectiveantitumor drug is rare, reversing MDR is especially important for a
better outcome. Fortunately, molecular-targeted therapy has
shown promise in preclinical studies, based on numerous signaling
pathways that play roles in the transcriptional regulation of MDR1/
P-gp. TRPS1 or other molecular oncogenes may be used as a poten-
tial target for reversing MDR as inhibitors/modulators of MDR1/P-
gp.
In conclusion, we have demonstrated that Trps1 promoted
MDR1/P-gp gene expression in osteosarcoma cell sublines, and it di-
rectly bound the MDR1/P-gp gene promoter GATA3 box-like se-
quence. Consequently, MDR and P-gp pump efﬂux function were
altered along with Trps1 expression. There is a positive correlation
between Trps1 andMDR1/P-gp in our clinical samples. In the future,
we may explore how Trps1 regulates MDR1/P-gp in vivo. Although
we have conﬁrmed that Trps1 directly binds to the promoter of
theMDR1/P-gp gene, there are stillmanyquestions about the effects
of the binding since Trps1 has been reported to repress transcrip-
tional activation mediated by other GATA factors [35].
Furthermore, our observations offer new perspectives for under-
standing anti-MDR treatments. In particular, we suggest Trps1 as a
newmolecular target for reversing drug resistance in osteosarcoma.
Fig. 6. Trps1 inhibits TGFbeta-1 expression and binds a site in the promoter of the human MDR1/P-gp gene. (A) Trps1 inhibits TGFbeta-1 mRNA expression in U2-OS cells. (B)
Western blots of TGFbeta-1 protein. (C) The direct binding site in MDR1/P-gp promoter. (D) In vivo characterization of Trps1 binding to the MDR1 promoter by ChIP assay.
Chromatin from U2-OS cells was immunoprecipitated with Trps1 antibody (lane 4), non-speciﬁc rabbit antibody (lane 3), unrelated antibody (lane 2), or without antibody
(lane 1) and then ampliﬁed by PCR using human MDR1 promoter-speciﬁc primers. Bottom panels show PCR ampliﬁcation of input DNA. (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001,
respectively).
M. Jia et al. / FEBS Letters 588 (2014) 801–810 809Additional clinical investigations with larger sample capability are
necessary to verify whether Trps1 in osteosarcoma cells is a bio-
marker for predicting sensitivity to several MDR1/P-gp speciﬁc
drugs.
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